Search This Blog

Thursday, March 4, 2021

Lipocine Publishes on Potential of LPCN 1144 in NASH, Hepatic Fibrosis

 Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the publication of preclinical results supporting the therapeutic potential of LPCN 1144 in the treatment of and non-alcoholic steatohepatitis ("NASH") and hepatic fibrosis. The results were featured in a paper entitled "Treatment Potential of LPCN 1144 on Liver Health and Metabolic Regulation in a Non–Genomic, High Fat Diet Induced NASH Rabbit Model" (Comeglio et al), published in the Journal of Endocrinological Investigation (https://doi.org/10.1007/s40618-021-01522-7).

https://www.prnewswire.com/news-releases/lipocine-announces-publication-in-journal-of-endocrinological-investigation-highlighting-the-potential-of-lpcn-1144-in-the-treatment-of-nash-and-hepatic-fibrosis-301240212.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.